Associated tags: Prostate cancer, Patient, Pharmaceutical industry, EPIX, SAN, ESSA, Conference, Webcast
Locations: NEW YORK, QUEBEC, BRITISH COLUMBIA, CALIFORNIA, CANADA
Retrieved on:
Tuesday, February 6, 2024
SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Feb. 6, 2024 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will be participating in a virtual fireside chat at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Tuesday, February 13, 2024, at 12:40 p.m.
Key Points:
- SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Feb. 6, 2024 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will be participating in a virtual fireside chat at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Tuesday, February 13, 2024, at 12:40 p.m.
- R. Parkinson, President, and Chief Executive Officer; Peter Virsik, Chief Operating Officer; and David S. Wood, Chief Financial Officer, will host and participate in one-on-one meetings.
- A live webcast of the fireside chat can be accessed in the Investors/Events & Presentations section of ESSA's website at www.essapharma.com .
- Following the event, the webcast will be archived on the ESSA website for 90 days.
Retrieved on:
Wednesday, November 8, 2023
SOUTH SAN FRANCISCO, Calif. and VANCOUVER, Canada, Nov. 8, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will be presenting at the Jefferies Healthcare Conference on Wednesday, November 15, 2023, at 8:30 a.m. GMT/ 3:30 a.m.
Key Points:
- SOUTH SAN FRANCISCO, Calif. and VANCOUVER, Canada, Nov. 8, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will be presenting at the Jefferies Healthcare Conference on Wednesday, November 15, 2023, at 8:30 a.m. GMT/ 3:30 a.m.
- R. Parkinson, President, and Chief Executive Officer; Peter Virsik, Chief Operating Officer; and David S. Wood, Chief Financial Officer, will host and participate in one-on-one meetings.
- A live webcast of the Jefferies presentation can be accessed in the Investors/Events & Presentations section of ESSA's website at www.essapharma.com .
- Following the event, the webcast will be archived on the ESSA website for 90 days.
Retrieved on:
Saturday, October 21, 2023
The poster presentation is available on the ESMO Digital Program and in the "Publications" section of the Company's website at www.essapharma.com .
Key Points:
- The poster presentation is available on the ESMO Digital Program and in the "Publications" section of the Company's website at www.essapharma.com .
- We look forward to further elucidating the potential clinical benefit of this combination in the randomized Phase 2 portion of the study which is currently underway."
- The data presented today are from the first four cohorts of patients in the Phase 1 dose escalation portion of the study.
- Enzalutamide reduces masofaniten exposure but twice daily dosing of masofaniten appears to mitigate the reduction and maintains clinically relevant drug exposures.
EPIX,
Chief commercial officer,
Pennsylvania State University,
N,
Genentech,
Lauren,
Government,
ESSA,
SAN,
Roivant Sciences,
Commercial,
Prostate cancer,
Pharmaceutical industry,
Microbiology,
New York University,
Marketing SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, June 6, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the appointment of Lauren Merendino, M.B.A., to its Board of Directors.
Key Points:
- SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, June 6, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the appointment of Lauren Merendino, M.B.A., to its Board of Directors.
- Ms. Merendino is a leading biopharmaceutical executive who brings over 25 years of commercial experience spanning 20+ disease states, including 15 years of leadership for oncology-specific portfolios.
- "Lauren's cross-functional expertise in guiding products through all stages of commercial development adds a valuable perspective that complements the skillset of our Board of Directors," stated Richard M. Glickman, L.L.D.
- (Hon), Chairman of ESSA's Board of Directors.
SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, June 1, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will be presenting at the Jefferies Healthcare Conference on Thursday, June 8, 2023 at 8:00 a.m. Eastern Time in New York.
Key Points:
- SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, June 1, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will be presenting at the Jefferies Healthcare Conference on Thursday, June 8, 2023 at 8:00 a.m. Eastern Time in New York.
- David R. Parkinson, President and Chief Executive Officer of ESSA Pharma; Peter Virsik, ESSA's Chief Operating Officer; and David S. Wood, ESSA's Chief Financial Officer, will host and participate in one-on-one meetings.
- A live webcast of the Jefferies presentation can be accessed in the Investors/Events & Presentations section of ESSA's website at www.essapharma.com .
- Following the event, the webcast will be archived on the ESSA website for 90 days.
SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, May 11, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will be presenting at the JMP Securities Life Sciences Conference on Tuesday, May 16, 2023 at 10:00 a.m. Eastern Time in New York.
Key Points:
- SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, May 11, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will be presenting at the JMP Securities Life Sciences Conference on Tuesday, May 16, 2023 at 10:00 a.m. Eastern Time in New York.
- David R. Parkinson, President and Chief Executive Officer of ESSA Pharma; Peter Virsik, ESSA's Chief Operating Officer; and David S. Wood, ESSA's Chief Financial Officer, will host and participate in one-on-one meetings.
- A live webcast of the JMP Securities presentation can be accessed in the Investors/Events & Presentations section of ESSA's website at www.essapharma.com .
- Following the event, the webcast will be archived on the ESSA website for 90 days.
SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, April 18, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will be presenting at the 2023 Bloom Burton & Co. Healthcare Investor Conference on Tuesday, April 25, 2023 at 2:00 p.m. Eastern Time.
Key Points:
- SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, April 18, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will be presenting at the 2023 Bloom Burton & Co. Healthcare Investor Conference on Tuesday, April 25, 2023 at 2:00 p.m. Eastern Time.
- David R. Parkinson, President and Chief Executive Officer of ESSA Pharma; Peter Virsik, ESSA's Chief Operating Officer; and David S. Wood, ESSA's Chief Financial Officer, will host and participate in one-on-one meetings.
- A live webcast of the Bloom Burton & Co. presentation can be accessed in the Investors/Events & Presentations section of ESSA's website at www.essapharma.com .
- Following the event, the webcast will be archived on the ESSA website for 90 days.
Retrieved on:
Thursday, November 10, 2022
SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Nov. 10, 2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will be participating in two upcoming investor conferences.
Key Points:
- SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Nov. 10, 2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will be participating in two upcoming investor conferences.
- R. Parkinson, President and Chief Executive Officer of ESSA Pharma, will participate in and host one-on-one meetings.
- Following the event, the webcast will be archived on the ESSA website for 90 days.
- ESSA is a clinical-stage pharmaceutical company focused on developing novel and proprietary therapies for the treatment of patients with prostate cancer.
Retrieved on:
Tuesday, September 13, 2022
Risk,
Department,
Dana–Farber Cancer Institute,
Twitter,
EDGAR,
N,
Biomarker,
Brown University,
Company,
Private Securities Litigation Reform Act,
Therapy,
Internal medicine,
Forward-looking statement,
Book,
Patient,
RNA,
Jerome,
Physician,
Memorial Sloan Kettering Cancer Center,
Board of directors,
MSK,
NASDAQ,
Harvard Medical School,
SAN,
Board,
Research,
Prostate cancer,
Oncology,
SEDAR,
Pharmaceutical industry,
Medical imaging,
Public relations,
Director,
Medicine SOUTH SAN FRANCISCO, CaliforniaandVANCOUVER, Canada, Sept. 13, 2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the appointment of Philip Kantoff, M.D., to its Board of Directors.
Key Points:
- SOUTH SAN FRANCISCO, CaliforniaandVANCOUVER, Canada, Sept. 13, 2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the appointment of Philip Kantoff, M.D., to its Board of Directors.
- Dr. Kantoff brings invaluable insight and experience to ESSA as a renowned medical oncologist and leader in the clinical development of new prostate cancer treatments.
- "Phil's breadth and quality of accomplishments are unmatched, and we are honored to welcome him to ESSA's Board of Directors," stated Richard M. Glickman, L.L.D.
- I look forward to advising and working with ESSA's Board of Directors and management team during this pivotal time," said Philip Kantoff, M.D.
SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, June 2, 2022 /PRNewswire/ - ESSA Pharma Inc.("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will be presenting at the 2022 Jefferies Healthcare Conference in New York City on Thursday, June 9, 2022 at 3:00 p.m. Eastern Time.
Key Points:
- SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, June 2, 2022 /PRNewswire/ - ESSA Pharma Inc.("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that the Company will be presenting at the 2022 Jefferies Healthcare Conference in New York City on Thursday, June 9, 2022 at 3:00 p.m. Eastern Time.
- David.
- R. Parkinson, President and Chief Executive Officer of ESSA Pharma, will participate in and host one-on-one meetings.
- David S. Wood, ESSA's Chief Financial Officer, will also be participating in the one-on-one meetings.
